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ume of the future liver remnant, and general condition of the 
patient. In patients with favorable features (solitary tumor, 
compensated Child-Pugh A cirrhosis, no portal hyperten-
sion), the reported 5-year survival rates range between 50 
and 70%. In specific cases, liver resection and LT may be com-
bined in the same patient.  Copyright © 2013 S. Karger AG, Basel 
 Background 
 Hepatocellular carcinoma (HCC) is one of the major 
health problems worldwide, and continues to grow be-
cause of its association with hepatitis B and C. The diag-
nosis and treatment of HCC has witnessed major chang-
es over the past decade. Until the early 1990s, HCC was a 
relatively rare malignancy that was typically diagnosed at 
an advanced disease stage. Nowadays, HCC represents 
the fifth most common malignancy worldwide and its 
mortality is third among all solid tumors, behind carcino-
mas of the lung and the colon  [1] . Despite recent im-
provements in screening, detection, surgical treatment 
and chemotherapy, the overall survival (OS) and recur-
rence-free survival of patients with HCC remains lower 
than that for most other solid tumors  [1, 2] . HCC typi-
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cally presents at an advanced stage with only a limited 
portion of cases being suitable for curative treatment 
strategies, some of which include surgical resection, liver 
ablative procedures and liver transplantation (LT)  [3] . 
Unfortunately, most patients are seen when the disease 
has reached a stage beyond curative treatment, leaving 
palliative care as the only alternative  [4–6] . This review 
will focus on the different medical and surgical treatment 
modalities in patients with HCC and will provide back-
ground to clinical cases presented at the Falk Symposium 
in Mainz, Germany 2012.
 Surgical Resection for HCC 
 Among curative treatment options for HCC, liver re-
section and transplantation are considered the mainstay 
of curative therapy  [7] . However, LT can only be pro-
posed in approximately 30% of patients with HCC due to 
limitations in donor graft availability and transplant cri-
teria in this particular setting  [3] . The selection of the pri-
mary treatment for HCC depends on tumor stage, func-
tional status of the liver and the general condition of the 
patient. When the liver parenchyma is normal, which is 
the less frequent situation, the treatment of choice con-
sists of surgical resection. However, most patients with 
HCC have an underlying chronic liver disease at the time 
of diagnosis. In this situation, LT is considered as the 
treatment of choice because it treats both the tumor and 
the underlying disease. Unfortunately, while progress has 
been made in the detection and screening of HCC, the 
low availability of liver grafts has been a major problem 
and many patients die on the waiting list. As such, liver 
resections also in patients with underlying chronic liver 
disease are becoming increasingly popular. This is attrib-
uted to the development of new surgical techniques and 
better preoperative assessment of patient risk factors as-
sociated with partial hepatectomy in this particular set-
ting  [8, 9] . To consider a liver resection in patients with 
HCC, three factors need to be integrated in the process of 
decision-making: (1) tumor stage, (2) quality and func-
tion of the underlying liver parenchyma, and (3) volume 
of the future liver remnant.
 (1) In general, solitary HCC lesions confined to the liver 
without vascular invasion with well-preserved hepatic 
function have the best outcomes. Although there are 
no strict criteria in terms of tumor size, tumor-associ-
ated predictors of poor outcome after liver resection 
include satellite nodules, size of lesion >5 cm, serum 
α-fetoprotein level >2,000 ng/ml, positive resection 
margins and Union for International Cancer Control 
(UICC) stages III or IV  [10] .
 (2) Almost 90% of HCC develop in patients with chronic 
underlying liver disease (hepatitis B, hepatitis C, alco-
holic liver disease, hemochromatosis and nonalcoholic 
steatohepatitis). Importantly, the risk of resection in 
these patients is directly related to a decrease in the ca-
pacity of the remnant liver to regenerate  [2] . As such, 
preoperative assessment of the underlying liver disease 
is of upmost clinical importance and is usually per-
formed using the Child-Pugh classification with the ad-
dition of quantitative liver function tests that have been 
developed to refine patient selection in this setting. 
Based on regional practice patterns that vary around 
the world, one of the most commonly used tests in this 
setting is the indocyanine green (ICG) clearance test. In 
fact, ICG, a tricarbocyanine dye that is completely and 
exclusively cleared by hepatocytes, is excreted into the 
bile in unmodified form and does not enter the entero-
hepatic circulation. As such, hepatectomy is possible in 
patients with less than 15% ICG retention, whereas pa-
tients with more than 20% ICG retention should be lim-
ited to minor or no resections  [11] . In this setting, it is 
particularly important to assess portal vein hyperten-
sion (PVH), as PVH is another important risk factor for 
postoperative liver failure and is usually considered a 
contraindication for major liver resection. Assessment 
of PVH can be achieved preoperatively by invasive he-
patic vein catheterization, upper endoscopy (esopha-
geal varices) and triphasic preoperative CT imaging 
(splenomegaly and/or venous collateral channels). In 
order to determine the presence or absence of cirrhosis, 
hepatic vein catheterization may be combined with 
transjugular liver biopsy of the nontumorous liver.
 (3) Assessment of the future liver remnant volume is per-
formed by CT volumetry. Whereas young patients 
with no underlying liver disease may undergo resec-
tion of up to 75% of the total liver volume, patients 
with chronic liver disease may undergo resections of 
more than 40–50% of the total liver volume.
 Orthotopic Liver Transplantation for HCC 
 HCC was one of the first indications for LT because it 
was postulated that this approach would not only elimi-
nate the tumor, but would also cure the underlying liver 
disease. However, early experience with LT for HCC in 
the 1980s was disappointing due to relatively high recur-
rence rates (>50%) and discouraging 5-year OS results 
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ranging from 10 to 35%  [12] . Since it appeared obvious 
that the success of LT for HCC depends on tumor load, 
strict selection criteria with regard to the size and number 
of tumor nodules [Milan criteria (MC): single HCC nod-
ule <5 cm or with up to 3 nodules <3 cm without macro-
vascular invasion] allowed achieving a 5-year OS of more 
than 70% and a 5-year recurrence rate of less than 10% 
 [13] . This evolution is mainly due to improvement of im-
aging techniques and surveillance programs that have 
been widely introduced; therefore, HCCs are being de-
tected earlier at a stage at which effective treatment is fea-
sible. In this context, LT for HCC currently represents 25 
and 35% of the indications for LT in Europe and the USA, 
respectively. The need to obtain the optimal benefit from 
the limited number of organs that are available has 
prompted the maintenance of selection criteria in order 
to list only those patients with early HCC who have the 
highest likelihood of survival after LT.
 Both tumor size and number are important factors of 
posttransplant recurrence inherent to the biology of HCC 
tumor that should be taken into account whenever select-
ing HCC patients beyond MC for LT. This has been well 
described and demonstrated in the ‘Metroticket’ concept 
(the farther you go in expansion of HCC staging criteria 
for selection for LT, the more you have to pay in terms of 
higher recurrence rates and poorer survival)  [14] . This 
model, based on the analysis of 1,556 patients transplanted 
at 36 centers, provides a linear correlation between tumor 
diameter and recurrence throughout the observed range. 
Survival was directly correlated with the size of the largest 
tumor, number of tumors and presence of microvascular 
invasion at explant pathology. Patients who fell within the 
‘up to 7 criteria’ (HCC with 7 as the sum of the largest tu-
mor diameter in cm and number of tumors) and without 
microvascular invasion achieved a 5-year OS of 71%. 
These ‘up to 7 criteria’ were compared with the Milan and 
University of California San Francisco criteria (1 tumor 
 ≤ 6.5 cm, or 2–3 nodules  ≤ 4.5 cm with total tumor diam-
eter  ≤ 8 cm) in a pathological study  [15] . The ‘Metroticket’ 
performed the best as a staging system with 5-year recur-
rence rate of 4% in patients within and 51% in patients 
beyond those ‘up to 7 criteria’. However, this staging sys-
tem is difficult to use in practice since the microvascular 
invasion cannot be accurately assessed by any preoperative 
work-up.
 The last international consensus conference on LT for 
HCC concluded that MC are currently the benchmark for 
selection of HCC patients for LT. A modest expansion of 
the number of potential candidates may be considered on 
the basis of the last studies reported above  [16] .
 Medical and Interventional Treatment 
 The majority of patients with HCC present with a dis-
ease stage beyond curative treatment (surgical resection 
or LT), leaving palliative care as the only alternative. 
Available medical and interventional treatment options 
depend on the size, number and location of tumors; pres-
ence or absence of underlying liver disease (fibrosis,
cirrhosis, portal hypertension); associate operative risk 
based on extent of underlying liver disease and comorbid 
diseases; overall performance status of the patient; paten-
cy of portal vein, and presence of metastatic disease.
 Local Ablative, Bridging and Downstaging Therapies 
 For patients with advanced HCC who are not candi-
dates for curative treatment, local therapies such as tran-
sarterial chemoembolization (TACE)/transarterial radio-
embolization (TARE), ethanol, radiofrequency and cryo-
ablation, as well as systemic chemotherapy remains the 
mainstay of therapy. Local ablative therapies are defined 
as the direct application of chemical or thermal therapies 
to a specific focal tumor in an attempt to achieve eradica-
tion or substantial tumor destruction. In patients with 
HCC, tumor ablative procedures are usually performed 
with a percutaneous image-guided approach. Intratu-
moral injections of ethanol, heat (via radiofrequency or 
microwave) or cold (cryoablation with liquid nitrogen) 
may be used to control tumors smaller than 4–5 cm. In 
general, these procedures are reserved for patients who 
do not meet the criteria for primary surgical resection, yet 
are candidates for a liver-directed procedure and/or LT.
 Radiofrequency ablation (RFA) is the delivery of ra-
diofrequency thermal energy to the HCC lesion causing 
necrosis of the tumor. During RFA, a high-frequency al-
ternating current is delivered from the tip of an electrode 
into the surrounding tissue. The ions within the tissue 
attempt to follow the direction of the alternating current 
resulting in friction and eventual heating of the tissue. As 
the tissue temperature elevates above 60   °   C, tumor cells 
begin to die resulting in an area of tumor necrosis. RFA 
can be performed surgically (laparotomy or laparosco-
py) or interventionally (image-guided percutaneous ap-
proach), and is the most commonly used local ablation 
modality in the treatment of patients with HCC lesions 
less than 4 cm in size  [17] . As such, some studies show 
good initial tumor control with an average local recur-
rence rate of 5–6% within the first 20 months  [18] . Even 
though recent reports on long-term outcome of RFA-
treated patients have shown that patients with Child-
Pugh A liver disease and early-stage HCC show 5-year 
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survival rates of as high as 50–70%, and may even reach 
76% in patients who meet the Barcelona Clinic Liver Can-
cer (BCLC) Classification criteria for surgical resection 
 [19, 20] , a recent randomized controlled trial comparing 
resection versus RFA alone in patients within the MC has 
demonstrated superior OS for the surgical arm (5-year 
survival: 75% for surgical resection vs. 54% for RFA; p = 
0.001)  [21] .
 TACE is a widely used palliative treatment for patients 
with HCC and employs the injection of an anticancer 
drug (Adriamycin or cisplatin), mixed with Lipidol into 
the hepatic artery or one of its branches, followed by arte-
rial embolization using Gelfoam particles or powder  [5] . 
Clinically, HCC tends to get its vascularization from the 
hepatic artery and for that reason TACE has proven to be 
effective in managing many patients with localized dis-
ease  [2, 22] . When mixed with Lipidol, Adriamycin and 
cisplatin are supposed to form a stable mixture that stays 
in close contact with the tumor for several weeks, thus 
enhancing the antitumor effect of the selected anticancer 
agent. In addition, Lipidol contributes to the emboliza-
tion of arterial vessels inside the tumor, and thereby helps 
to retain the cytotoxic drug in the tumor  [23] .
 TARE is a locoregional therapy, but has – in contrast 
to chemotherapy – the ability to destroy liver tumors re-
gardless of histologic origin. Because of the high radio-
sensitivity of liver tissue and the fact that the liver moves 
during breathing, external beam radiation has had a lim-
ited role in treating liver disease despite recent techno-
logical advances  [24] . In contrast, with internal radiation 
through local delivery of yttrium-90 microspheres (ra-
dioembolization) into the arterial circulation, a radiation 
dose high enough for tumor control (70–90 Gy) may be 
delivered to the tumor without extensive damage to the 
surrounding nontumorous liver. Radioembolization in 
the treatment of liver tumors has attracted significant in-
terest over the last decade both for the treatment of non-
resectable HCC as well as downsizing before resection 
and LT  [25] . The overall tumor response rates in patients 
with HCC yield from 78 to 89%  [26] . Even though no ran-
domized controlled trial has yet to compare TARE versus 
TACE, two retrospective series did not observe a differ-
ence in OS between the two groups, despite a longer pro-
gression-free survival in the TARE group  [27, 28] . The 
advantages of TARE as a costly and complex procedure 
need to be determined in prospective clinical trials.
 Bridging strategies circumscribe locoregional thera-
pies employed in patients already on the waiting list for 
LT. Bridging strategies have been introduced to reduce 
waiting list mortality when transplantation cannot be ad-
ministered immediately. In addition, interest concerning 
LT of patients with HCC beyond the MC has shifted late-
ly from expanded criteria to tumor downstaging, gener-
ally by nonsurgical means, to reduce the size and/or num-
ber of tumors from beyond to within MC. As such, sev-
eral strategies have been adopted lately as bridging 
therapies: TACE/TARE, RFA or resection.
 The rationale for using TACE as a neoadjuvant thera-
py prior to LT is twofold: to control tumor growth while 
the patient is on the waiting list and to induce tumor ne-
crosis that may reduce tumor dissemination during LT. 
Overall, it has been shown that TACE – while not increas-
ing the complication rate for LT – does not improve OS 
after LT neither for early nor for advanced HCC  [22] . As 
such, a retrospective case control study investigated the 
results of TACE on outcome after LT  [29] and found no 
significant difference in the 5-year survival rate (69% with 
TACE vs. 64% without TACE), even though tumor recur-
rences were less frequent in the TACE/LT group (13 vs. 
23%). Therefore, it appears that TACE is not harmful and 
may allow reducing dropout rates from the waiting list.
 In pathological studies, the results of RFA appear to be 
superior to TACE in terms of local tumor control  [30, 31] . 
Mazzaferro et al.  [32] showed in patients who underwent 
RFA as a bridge treatment to LT that tumor size greater 
than 3 cm or the presence of large abutting vessels result 
in a drop of the rate of complete tumor necrosis to 50% or 
less. Thus, RFA appears to be safe as a bridging therapy for 
HCC less than 3 cm. However, its effect to decrease the 
dropout rates still needs to be proven in further prospec-
tive trials. Radioembolization represents 5–10% of bridg-
ing locoregional treatment in the organ procurement and 
transplant network registry, but data available on its im-
pact are scarce and further experience is needed  [33] . In a 
recent study looking at the radiopathological correlation 
of HCC treated with internal radiation using yttrium-90 
microspheres, all targeted lesions had some histologic ne-
crosis and 60% of them showed complete necrosis  [31] .
 In compensated cirrhotic patients with HCC and a 
long anticipated time on the waiting list, liver resection 
followed by listing for LT could be applied  [33] . The deci-
sion for resection depends on liver function and the size 
and location of the tumor. This strategy allows control of 
the tumor and a better assessment of its pathological fea-
tures. In case of bad prognosis factors (poor differentia-
tion, microvascular invasion, absence of capsule), a pre-
emptive LT (bridge LT) could be advised (i.e. before re-
currence but after sufficient observation). If the tumor 
does not show any risk factors for recurrence, LT may be 
postponed and offered only in cases of tumor recurrence 
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(salvage LT). Liver resection for small solitary HCC in 
compensated cirrhosis yields an OS rate comparable to 
LT  [34] . Despite a significant recurrence rate, close imag-
ing monitoring after liver resection allows salvage LT in 
two thirds of the patients with recurrence in intention-to-
treat analysis  [34] .
 Bridging strategies with locoregional treatments are 
probably beneficial in patients when a long waiting time 
is likely because it decreases dropout rates without im-
pairing posttransplant outcomes. This strategy seems to 
be indicated for T2 tumor (solitary tumor with vascular 
invasion or multiple tumors none more than 5 cm) and 
patients likely to wait longer than 6 months  [33] . Patho-
logical studies suggest that there is a marginal advantage 
for RFA in terms of local ablation. Newer strategies com-
bining TACE and RFA or using yttrium-90 may be prom-
ising. Finally, liver resection followed by salvage LT in 
case of recurrence should be restricted to patients with 
favorable oncological factors.
 Systemic Chemotherapy and Targeted Agents 
 For patients with advanced HCC who are not candi-
dates for surgical resection, LT or localized ablative thera-
pies, systemic chemotherapy has never shown a significant 
advantage compared to best supportive care. Unfortunate-
ly, HCC is a relatively chemoresistant tumor with response 
rates as low as 10% for single-agent chemotherapy. Doxo-
rubicin has initially been licensed for the use as first-line 
treatment in unresectable HCC. Even though being the 
standard of care for decades, doxorubicin is usually not 
well tolerated and seems to be less effective in HCC pa-
tients with underlying liver disease. Recently cisplatin-
based combination regimens have been shown to improve 
response rates to up to 20%, but to date, no survival advan-
tage as compared to best supportive care could be shown 
 [35] . Moreover, some of these regimens cause considerable 
toxicity and are therefore not well tolerated, especially in 
patients with cirrhosis and other comorbid diseases.
 Targeted agents or antiangiogenesis agents (sorafenib, 
bevacizumab, cetuximab) have recently been employed 
or tested in the treatment of advanced HCC  [6] . Only 
sorafenib, a small-molecule multityrosine-kinase inhibi-
tor, has been shown to extend survival in patients with 
advanced HCC and has opened the door for other
possible adjuvant antiangiogenic treatment strategies 
(SHARP trial)  [36] . However, the median survival im-
provement of 2.8 months (in the Western world  [37] ) and 
1.7 months (in the Eastern world  [38] ) is, to many outside 
the field of oncology, regarded as marginal. Currently, 
sorafenib is the only FDA-approved antineoplastic agent 
for HCC  [39] .
 Conclusion 
 Due to the actual allocation system based in Europe 
and the United States, not all patients with HCC occur-
ring in normal liver or in an underlying chronic liver dis-
ease can have access to LT. Therefore, liver resection has 
taken an important place in the curative treatment for 
HCC. This surgery can be performed safely providing 
that the liver function was not previously altered and 
there is adequate future liver remnant volume and ab-
sence of portal hypertension. If the waiting time for LT is 
predicted to be prolonged, the risk of tumor progression 
and either dropout from the list or interval dissemination 
with posttransplant tumor recurrence is recognized. 
Then liver-directed therapy like TACE, TARE, RFA or 
microwave ablation should be used to decrease these 
risks, and resection and LT should be associated rather 
than opposed.
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